open access

Vol 84, No 5 (2016)
ORIGINAL PAPERS
Submitted: 2016-09-27
Accepted: 2016-09-27
Get Citation

Effect of obesity and metabolic syndrome on severity, quality of life, sleep quality and inflammatory markers in patients of asthma in India

Mandeep Singh, Nitesh Gupta, Raj Kumar
DOI: 10.5603/PiAP.2016.0032
·
Pneumonol Alergol Pol 2016;84(5):258-264.

open access

Vol 84, No 5 (2016)
ORIGINAL PAPERS
Submitted: 2016-09-27
Accepted: 2016-09-27

Abstract

INTRODUCTION: The study aimed to compare the effect of obesity with and without metabolic syndrome on asthma severity, quality of life, sleep quality, sleep disordered breathing and inflammatory markers as compared to non-obese asthma patients.

MATERIAL AND METHODS: 60 asthma patients recruited for the study were divided equally into non-obese (NOA), obese without metabolic syndrome (OANMS) and obese with metabolic syndrome (OAMS) groups. Study cohorts were assessed for severity of asthma, quality of life and quality of sleep using questionnaires and inflammatory markers (FENO, hs-CRP, IL-5, IL-6 and leptin). Institutional ethical committee approved the study.

RESULTS: The results suggests OAMS patients may be a subtype of asthmatics having significantly severe asthma (p < 0.05), poor quality of life (p  < 0.05), high risk of OSA (p < 0.05), decreased lung volumes (FRC) (p < 0.05), higher levels of inflammatory markers (leptin and IL-6) (p  < 0.05), and high incidence of sleep disordered breathing (p < 0.05) in comparison to NOA and OANMS patients.

CONCLUSIONS: The present study has shown that obese asthmatics especially with metabolic syndrome represent a subtype of asthmatic population. Hence, the treatment of metabolic syndrome may be necessary in addition to asthma to achieve optimal control.

Abstract

INTRODUCTION: The study aimed to compare the effect of obesity with and without metabolic syndrome on asthma severity, quality of life, sleep quality, sleep disordered breathing and inflammatory markers as compared to non-obese asthma patients.

MATERIAL AND METHODS: 60 asthma patients recruited for the study were divided equally into non-obese (NOA), obese without metabolic syndrome (OANMS) and obese with metabolic syndrome (OAMS) groups. Study cohorts were assessed for severity of asthma, quality of life and quality of sleep using questionnaires and inflammatory markers (FENO, hs-CRP, IL-5, IL-6 and leptin). Institutional ethical committee approved the study.

RESULTS: The results suggests OAMS patients may be a subtype of asthmatics having significantly severe asthma (p < 0.05), poor quality of life (p  < 0.05), high risk of OSA (p < 0.05), decreased lung volumes (FRC) (p < 0.05), higher levels of inflammatory markers (leptin and IL-6) (p  < 0.05), and high incidence of sleep disordered breathing (p < 0.05) in comparison to NOA and OANMS patients.

CONCLUSIONS: The present study has shown that obese asthmatics especially with metabolic syndrome represent a subtype of asthmatic population. Hence, the treatment of metabolic syndrome may be necessary in addition to asthma to achieve optimal control.

Get Citation

Keywords

obesity, metabolic syndrome, asthma, SGRQ, FENO

About this article
Title

Effect of obesity and metabolic syndrome on severity, quality of life, sleep quality and inflammatory markers in patients of asthma in India

Journal

Advances in Respiratory Medicine

Issue

Vol 84, No 5 (2016)

Pages

258-264

DOI

10.5603/PiAP.2016.0032

Bibliographic record

Pneumonol Alergol Pol 2016;84(5):258-264.

Keywords

obesity
metabolic syndrome
asthma
SGRQ
FENO

Authors

Mandeep Singh
Nitesh Gupta
Raj Kumar

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl